Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies-Reference-Cited by-同舟云学术

Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies

Published:2012-07-05 Issue:11 Volume:21 Page:1202-1215
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Lo Re Vincent,Haynes Kevin¹,Ming Eileen E.,Wood Ives Jennifer²,Horne Laura N.³,Fortier Kimberly¹,Carbonari Dena M.¹,Hennessy Sean¹,Cardillo Serena⁴,Reese Peter P.,Reddy K. Rajender⁴,Margolis David,Apter Andrea,Kimmel Stephen E.,Roy Jason¹,Freeman Cristin P.¹,Razzaghi Hanieh¹,Holick Crystal N.⁵,Esposito Daina B.⁵,Van Staa Tjeerd-Pieter⁶,Bhullar Harshvinder⁷,Strom Brian L.

Affiliation:

1. Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, Perelman School of Medicine; University of Pennsylvania; Philadelphia; PA; USA

2. Department of Global Pharmacovigilance and Epidemiology; Bristol-Myers Squibb; Hopewell; NJ; USA

3. Department of Global Epidemiology; AstraZeneca Pharmaceuticals LP; Wilmington; DE; USA

4. Department of Medicine, Perelman School of Medicine; University of Pennsylvania; Philadelphia; PA; USA

5. Department of Safety and Epidemiology; HealthCore, Inc.; Wilmington; DE; USA

6. General Practice Research Database; Medicines and Healthcare Products Regulatory Agency; London; UK

7. Depatment of Medical Research; Cegedim Strategic Data Medical Research; London; UK

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Reference73 articles.

1. Progress in the oral treatment of type 2 diabetes: update on DPP-IV inhibitors;Salvatore;Curr Diabetes Rev,2009

2. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus;Tahrani;Adv Ther,2009

3. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes;Rosenstock;Diabetes Obes Metab,2008

4. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial;Jadzinsky;Diabetes Obes Metab,2009

5. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone;DeFronzo;Diabetes Care,2009

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Validity of ICD‐10‐CM diagnoses to identify hospitalizations for serious infections among patients treated with biologic therapies;Pharmacoepidemiology and Drug Safety;2021-05-03

2. Encounter Databases;Pharmacoepidemiology;2019-10-18

3. Concordance of hospitalizations between Clinical Practice Research Datalink and linked Hospital Episode Statistics among patients treated with oral antidiabetic therapies;Pharmacoepidemiology and Drug Safety;2019-07-22

4. Validity of diagnostic codes to identify hospitalizations for infections among patients treated with oral anti-diabetic drugs;Pharmacoepidemiology and Drug Safety;2017-12-18

5. Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes;BMJ Open Diabetes Research & Care;2017-07